Benjamin Slupecki News Today

With long-term opportunities available across multiple industry groups, healthcare ETFS such as HART have the makings of a 2023 redemption.

The healthcare sector isn’t setting the investment world ablaze this year, but it is outperforming the broader market, underscoring its defense posture.

Healthcare stocks are being dragged lower by acute broader market weakness this year, but the sector isn’t performing as poorly as the S&P 500.

Investor fear of higher inflation, rising interest rates, and a possible recession have whipsawed markets and pushed the S&P 500 into a bear market for the first time since early in the pandemic.

As of the end of October, the Consumer Price Index (CPI) surged a staggering 6.2% on a year-over-year basis.

June 3, 2021 Growth and value are perhaps the most obvious rivals in the factor universe. The two are the most paired in factor conversations, so it stands to reason that if one is performing well, market participants are likely to take unfavorable views of the other. However, not all growth funds are cut of the same cloth, meaning investors holding those products this year are encountering varying outcomes this year as growth stocks trail value rivals. As Morningstar analyst Benjamin Slupeck...